1. Home
  2. GGG vs UTHR Comparison

GGG vs UTHR Comparison

Compare GGG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graco Inc.

GGG

Graco Inc.

HOLD

Current Price

$83.39

Market Cap

13.8B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$489.62

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGG
UTHR
Founded
1926
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
GGG
UTHR
Price
$83.39
$489.62
Analyst Decision
Buy
Buy
Analyst Count
2
12
Target Price
$94.00
$495.08
AVG Volume (30 Days)
883.0K
424.3K
Earning Date
01-26-2026
10-29-2025
Dividend Yield
1.32%
N/A
EPS Growth
3.48
16.08
EPS
2.93
26.38
Revenue
$2,192,120,000.00
$3,128,400,000.00
Revenue This Year
$6.75
$13.64
Revenue Next Year
$4.83
$5.78
P/E Ratio
$28.50
$18.55
Revenue Growth
2.85
13.50
52 Week Low
$72.06
$266.98
52 Week High
$91.00
$492.62

Technical Indicators

Market Signals
Indicator
GGG
UTHR
Relative Strength Index (RSI) 57.98 68.10
Support Level $81.32 $470.13
Resistance Level $83.16 $492.62
Average True Range (ATR) 1.46 10.72
MACD 0.34 -0.53
Stochastic Oscillator 84.01 89.55

Price Performance

Historical Comparison
GGG
UTHR

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: